Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00603668 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL
A Phase 1 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00603668 is a Phase 1 study that has completed, run by Gilead Sciences. The registered enrollment target is 19 participants.
The verdict
NCT00603668, a Phase 1 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study will test different doses of anti-CD74 antibody in patients with NHL and/or CLL.
Interventions
- BIOLOGICAL milatuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00603668
The ClinicalTrials.gov registry entry for NCT00603668 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which milatuzumab is the first listed.
NCT00603668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00603668 about?
NCT00603668 is a clinical study titled "Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL". This study will test different doses of anti-CD74 antibody in patients with NHL and/or CLL.
What is the current status of trial NCT00603668?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2008-08. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00603668?
The interventions under investigation include: milatuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00603668?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.